Skip to content Skip to footer
PharmaShots Interview In Conversation with Pyxis’ CMO Jay M. Feingold, Where he Shares Insights on the addition of In-Licensed & Internal IO Assets

PharmaShots Interview: In Conversation with Pyxis’ CMO Jay M. Feingold, Where he Shares Insights on the addition of In-Licensed & Internal IO Assets

Shots: Jay talked about the in-licensing of an IND-ready immuno-oncology (IO) candidate, anti-Siglec-15 Mab to the pipeline Jay also spoke about the company’s IO targets and other under development immunotherapies In addition, the interview provided the corporate and financial updates of the Pyxis Oncology Smriti: Can you tell us something about your in-licensed Mab anti-Siglec-15,…

Read more

Sign Up to Our Newsletter

Be the first to know the latest updates

[mc4wp_form id="13387" element_id="style-1"]